Editorials

Rosiglitazone and implications for pharmacovigilance

BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39245.502546.BE (Published 14 June 2007) Cite this as: BMJ 2007;334:1233
  1. Dhruv Kazi, internal medicine physician
  1. London School of Economics, London WC2A 2AE
  1. d.s.kazi{at}lse.ac.uk

    Postsurveillance data should be systematically collected, timely, and publicly available

    On 21 May 2007, the New England Journal of Medicine published a meta-analysis of 42 trials of rosiglitazone (Avandia, GlaxoSmithKline) for treating type 2 diabetes mellitus. It found that the drug was associated with an increased risk of myocardial infarction (odds ratio 1.43; 95% confidence interval 1.03 to 1.98; P=0.03) and death from cardiovascular causes (1.64; 0.98 to 2.74; P=0.06).1

    Rosiglitazone, a thiazolidinedione, is an agonist at the peroxisome-proliferator activated receptors in cell nuclei. These receptors modulate the expression of a host of genes, and glycaemic control is achieved primarily through increased insulin sensitivity in peripheral tissues. Rosiglitazone was approved by the US Food and Drug Administration (FDA) in 1999 and by the centralised process of the European Medicines Agency (EMEA) in 2000. Its popularity has increased steadily, with more than one million prescriptions written in the one year period ending March 2006 in England alone—a 22% increase over the previous year.2 However, the recently published meta-analysis raises serious questions about the drug's safety.

    Meta-analyses have unique strengths and weaknesses and this one is no exception.3 Its singular strength is the statistical power generated by data on 15 560 patients from published and unpublished trials. However, it includes clinically heterogeneous trials and criteria used …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe